BioNTech Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into BioNTech (BNTX)
BioNTech investors absorbed a 7.13% loss when the AHEAD-MERIT trial of BNT113 missed its progression-free survival primary endpoint. An investigation is underway into whether the Company's statements about its mRNA oncology programs gave shareholders an accurate picture.
NEW YORK, Oct. 14, 2026 /PRNewswire/ -- Every $10,000 held in BioNTech SE (NASDAQ: BNTX) shrank by roughly $713 after the Company announced that its Phase 2/3 AHEAD-MERIT trial of BNT113 plus pembrolizumab did not achieve its progression-free survival primary endpoint versus pembrolizumab alone. Shares fell approximately 7.13%. If that loss landed in your brokerage account, you are encouraged to submit your BNTX loss information now. You may also contact Joseph E. Levi, Esq. via email at [email protected] or by telephone at (888) SueWallSt.
The losses scale with position size. A $50,000 stake lost roughly $3,500. A $250,000 stake lost roughly $17,500. Shareholders who sold into the decline have already realized those losses. Those still holding are carrying them.
Market coverage tied the move to the AHEAD-MERIT result. Reports said the readout reduced investor confidence in BioNTech's oncology pipeline. SueWallSt notifies investors of a pending investigation into potential securities law violations on behalf of BNTX investors who suffered losses.
If the AHEAD-MERIT readout cost you money, have your BNTX losses evaluated or reach Joseph E. Levi, Esq. at [email protected] or (888) SueWallSt.
WHY SUEWALLST: SueWallSt is powered by Levi & Korsinsky LLP. Levi & Korsinsky LLP has established itself as a nationally-recognized securities litigation firm that has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. The firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States.
Frequently Asked Questions About the BNTX Investigation
Q: How much did BNTX stock drop?A: Shares fell approximately 7.13% after the Company disclosed that the Phase 2/3 AHEAD-MERIT trial of BNT113 plus pembrolizumab did not achieve its progression-free survival primary endpoint versus pembrolizumab alone. Investors who purchased shares at allegedly inflated prices and suffered losses may be eligible to seek compensation.
Q: Who is eligible to participate in the BNTX investigation?A: Investors who purchased BNTX stock or securities and suffered financial losses may be eligible. Eligibility is based on purchase date and documented losses -- not on whether you still hold the shares.
Q: Which statements are being investigated as potentially misleading?A: The investigation concerns whether BioNTech made potentially false or misleading statements regarding the clinical prospects and progress of BNT113 and its mRNA cancer immunotherapy programs. When the Company disclosed that AHEAD-MERIT did not achieve its progression-free survival primary endpoint, the stock price declined.
Q: What do BNTX investors need to do right now?A: Investors may gather brokerage records showing purchase dates, share quantities, and prices paid. Submit your information for a no-cost, no-obligation evaluation of your potential recovery. No immediate action is required to remain eligible to participate in the investigation.
Q: What documents do I need to participate?A: You will need brokerage statements or trade confirmations showing purchase dates, share quantities, prices paid, and any subsequent sale dates and prices.
Q: What if I already sold my BNTX shares -- can I still recover losses?A: Yes. Eligibility is based on when you purchased, not whether you still hold the shares. Investors who bought BNTX and sold at a loss may still participate in the investigation.
Q: What if my BNTX losses are small -- is it still worth contacting a lawyer?A: Yes. There is no minimum loss amount required to participate in the investigation.
Q: What if I live outside the United States?A: U.S. securities investigations generally cover purchases on U.S. exchanges regardless of the investor's country of residence. BioNTech's American Depositary Shares trade on the NASDAQ under the ticker BNTX.
Q: What does it cost me to participate?A: There is no upfront cost to submit your information and review whether you may be eligible to recover. Should you choose to participate in any resulting action, these matters are generally handled on a contingency basis, with any attorneys' fees and expenses subject to court approval.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
33 Whitehall Street, 27th Floor
New York, NY 10004
[email protected]
Tel: (888) SueWallSt
Fax: (212) 363-7171
Attorney Advertising. Prior results do not guarantee similar outcomes.
SOURCE SueWallSt.com